首页> 外文期刊>Open Journal of Radiology >Implantable Venous Access Ports for Chemotherapy in Lung Cancer Patients: Comparison of the Femoral and Subclavian Vein Approaches without Guidance
【24h】

Implantable Venous Access Ports for Chemotherapy in Lung Cancer Patients: Comparison of the Femoral and Subclavian Vein Approaches without Guidance

机译:肺癌患者化学疗法的植入式静脉通路:未经指导的股骨和锁骨下静脉入路的比较

获取原文
       

摘要

Background: The goal of this study was to retrospectively compare the initial success rate and rate of intraoperative and late complications between the femoral and subclavian vein approaches used to implant venous access ports without guidance in lung cancer patients. Methods: We conducted a retrospective review of total 163 lung cancer patients who underwent implantations of a central venous access port for chemotherapy. 95 patients received the ports by the femoral vein blind-puncture technique and 68patients had the port implanted via the subclavian vein blind-puncture technique. The initial success rate of port implantation and the frequency of occurrence of complications were calculated. Results: The primary success rate of venous port implantation was 93.7% for femoral approach and 88.2% for the subclavian approach respectively (p < 0.05). Intraoperative complications developed in two patients (2.1%) in the femoral approach group and in five patients (7.4%) in the subclavian approach group. Although a higher intraoperative complication ratio for the subclavian approach was encountered compared to that for the femoral vein approach, there was no statistically significant difference (p = 0.103). Nor was there any statistically significant difference in terms of the occurrence of late complications. Conclusions: Venous access port implantation via the femoral vein approach is safe, and its success rate is very high, with the equal complication rates comparable to the subclavian approach. This approach avoids many of the intraoperative complications. Thus, the femoral vein approach for implanting a venous access port in lung cancer patients should be considered a valid, and safe technique.
机译:背景:本研究的目的是回顾性比较肺癌患者在无指导的情况下用于植入静脉通路的股静脉和锁骨下静脉入路的初始成功率和术中及后期并发症的发生率。方法:我们对总共163例接受中心静脉通路进行化疗的肺癌患者进行了回顾性研究。 95例患者通过股静脉盲穿术接受了端口,68例患者通过锁骨下静脉盲穿术进行了端口植入。计算了端口植入的初始成功率和并发症发生的频率。结果:股静脉入路的静脉端口植入的主要成功率为93.7%,锁骨下入路的成功率为88.2%(p <0.05)。股骨入路组中有2例(2.1%)发生术中并发症,锁骨下入路组中有5例(7.4%)发生术中并发症。尽管锁骨下入路的术中并发症发生率比股静脉入路的术中并发症发生率高,但差异无统计学意义(p = 0.103)。就晚期并发症的发生而言,也没有统计学上的显着差异。结论:通过股静脉入路静脉通路植入是安全的,其成功率很高,其并发症发生率与锁骨下入路相当。这种方法避免了许多术中并发症。因此,在肺癌患者中植入静脉通路的股静脉入路应该被认为是一种有效且安全的技术。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号